Cogent Biosciences, Inc.
COGT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $233 | $174 | $122 | $56 |
| G&A Expenses | $43 | $34 | $26 | $20 |
| SG&A Expenses | $43 | $34 | $26 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $276 | $208 | $148 | $76 |
| Operating Income | -$276 | -$208 | -$148 | -$76 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $20 | $16 | $8 | $3 |
| Pre-Tax Income | -$256 | -$192 | -$140 | -$72 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$256 | -$192 | -$140 | -$72 |
| % Margin | – | – | – | – |
| EPS | -2.46 | -2.42 | -2.26 | -1.85 |
| % Growth | -1.7% | -7.1% | -22.2% | – |
| EPS Diluted | -2.46 | -2.42 | -2.26 | -1.85 |
| Weighted Avg Shares Out | 104 | 80 | 59 | 39 |
| Weighted Avg Shares Out Dil | 104 | 80 | 59 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18 | $13 | $4 | $0 |
| Interest Expense | $0 | $0 | $4 | $0 |
| Depreciation & Amortization | $4 | $4 | $6 | $2 |
| EBITDA | -$272 | -$205 | -$142 | -$74 |
| % Margin | – | – | – | – |